Patents by Inventor Laman Al-Razzak
Laman Al-Razzak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6521651Abstract: A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and, optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).Type: GrantFiled: September 10, 1999Date of Patent: February 18, 2003Assignee: Abbott LaboratoriesInventors: John Lipari, Laman A. Al-Razzak, Soumojeet Ghosh, Rong Gao, Dilip Kaul
-
Publication number: 20030032619Abstract: A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and, optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).Type: ApplicationFiled: May 24, 2002Publication date: February 13, 2003Inventors: John Lipari, Laman A. Al-Razzak, Soumojeet Ghosh, Rong Gao, Dilip Kaul
-
Patent number: 6458818Abstract: A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and, optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).Type: GrantFiled: July 2, 1999Date of Patent: October 1, 2002Assignee: Abbott LaboratoriesInventors: John Lipari, Laman A. Al-Razzak, Soumojeet Ghosh, Rong Gao, Dilip Kaul
-
Patent number: 6232333Abstract: A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and, optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).Type: GrantFiled: November 7, 1997Date of Patent: May 15, 2001Assignee: Abbott LaboratoriesInventors: John Lipari, Laman A. Al-Razzak, Soumojeet Ghosh, Rong Gao, Dilip Kaul
-
Patent number: 6010718Abstract: Disclosed is a pharmaceutical composition for extended release of an erythromycin derivative in the gastrointestinal environment. The composition comprises an erythromycin derivative and a pharmaceutically acceptable polymer so that, when ingested orally, the composition induces statistically significantly lower C.sub.max in the plasma than an immediate release composition of the erythromycin derivative while maintaining bioavailability and minimum concentration substantially equivalent to that of the immediate release composition of the erythromycin derivative upon multiple dosing. The compositions of the invention have an improved taste profile and reduced gastrointestinal side effects as compared to those for the immediate release composition.Type: GrantFiled: April 11, 1997Date of Patent: January 4, 2000Assignee: Abbott LaboratoriesInventors: Laman Al-Razzak, Sheri L. Crampton, Linda E. Gustavson, Ho-Wah Hui, Nelly Milman, Susan J. Semla
-
Patent number: 6008192Abstract: Binary pharmaceutical compositions comprising (i) a cyclosporine compound, (ii) a hydrophilic phase and (iii) a surfactant provide bioavailability of the active ingredient which is equivalent to that provided by ternary compositions, but without the need for a lipophilic phase.Type: GrantFiled: March 12, 1998Date of Patent: December 28, 1999Assignee: Abbott LaboratoriesInventors: Laman A. Al-Razzak, Panayiotis Pericleous Constantinides, Dilip Kaul, John M. Lipari, Lisa L. McChesney-Harris, Bashar Y. Abdullah
-
Patent number: 5948436Abstract: A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a pharmaceutically acceptable alcohol. The composition can optionally comprise a pharmaceutically acceptable acid or a combination of pharmaceutically acceptable acids. The solution can optionally be encapsulated in hard gelatin capsules or soft elastic gelatin capsules. The solution can optionally be granulated with a pharmaceutically acceptable granulating agent.Type: GrantFiled: March 13, 1995Date of Patent: September 7, 1999Assignee: Abbott LaboratoriesInventors: Laman A. Al-Razzak, Kennan C. Marsh, Dilip Kaul, Lourdes P. Manning
-
Patent number: 5876749Abstract: A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a pharmaceutically acceptable alcohol. The composition can optionally comprise a pharmaceutically acceptable acid or a combination of pharmaceutically acceptable acids. The solution can optionally be encapsulated in hard gelatin capsules or soft elastic gelatin capsules. The solution can optionally be granulated with a pharmaceutically acceptable granulating agent.Type: GrantFiled: May 4, 1995Date of Patent: March 2, 1999Assignee: Abbott LaboratoriesInventors: Laman A. Al-Razzak, Kennan C. Marsh, Dilip Kaul, Lourdes P. Manning
-
Patent number: 5725878Abstract: A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a pharmaceutically acceptable alcohol. The composition can optionally comprise a pharmaceutically acceptable acid or a combination of pharmaceutically acceptable acids. The solution can optionally be encapsulated in hard gelatin capsules or soft elastic gelatin capsules. The solution can optionally be granulated with a pharmaceutically acceptable granulating agent.Type: GrantFiled: May 4, 1995Date of Patent: March 10, 1998Assignee: Abbott LaboratoriesInventors: Laman A. Al-Razzak, Kennan C. Marsh, Dilip Kaul, Lourdes P. Manning
-
Patent number: 5610193Abstract: A solid pharmaceutical composition is disclosed which comprises a pharmaceutically acceptable adsorbent or a mixture of pharmaceutically acceptable adsorbents to which is adsorbed a mixture of (1) a pharmaceutically acceptable organic solvent or a mixture of pharmaceutically acceptable organic solvents, (2) an HIV protease inhibiting compound and (3) one or more pharmaceutically acceptable acids. The solid composition can optionally be encapsulated in a hard gelatin capsule.Type: GrantFiled: May 22, 1996Date of Patent: March 11, 1997Assignee: Abbott LaboratoriesInventors: Laman A. Al-Razzak, Kennan C. Marsh, Richard A. Pyter
-
Patent number: 5559158Abstract: A solid pharmaceutical composition is disclosed which comprises a pharmaceutically acceptable adsorbent or a mixture of pharmaceutically acceptable adsorbents to which is adsorbed a mixture of (1) a pharmaceutically acceptable organic solvent or a mixture of pharmaceutically acceptable organic solvents, (2) an HIV protease inhibiting compound and (3) one or more pharmaceutically acceptable acids. The solid composition can optionally be encapsulated in a hard gelatin capsule.Type: GrantFiled: August 31, 1994Date of Patent: September 24, 1996Assignee: Abbott LaboratoriesInventors: Laman A. Al-Razzak, Kennan C. Marsh, Richard A. Pyter
-
Patent number: 5484801Abstract: A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a mixture of (1) (a) a solvent selected from propylene glycol and polyethylene glycol or (b) a solvent selected from polyoxyethyleneglycerol triricinoleate, polyethylene glycol 40 hydrogenated castor oil, fractionated coconut oil, polyoxyethylene (20) sorbitan monooleate and 2-(2-ethoxyethoxy)ethanol or (c) a mixture thereof and (2) ethanol or propylene glycol.Type: GrantFiled: May 12, 1995Date of Patent: January 16, 1996Assignee: Abbott LaboratoriesInventors: Laman A. Al-Razzak, Kennan C. Marsh, Lourdes P. Manning, Dilip Kaul
-
Patent number: 5334589Abstract: Compositions of a quinolone carboxylic acids useful for oral or parenteral administration to a human or veterinary patient are disclosed which comprise quinolone carboxylic acid--metal ion--acid complexes in combination with a physiologically acceptable carrier and having a pH of about 4 to about 10, as well as a method for their production and use in treatment. Such compositions are found to cause unexpectedly low levels of vein irritation upon intravenous administration.Type: GrantFiled: June 25, 1992Date of Patent: August 2, 1994Assignee: Abbott LaboratoriesInventors: Laman A. Al-Razzak, Francisco J. Alvarez
-
Patent number: 4980343Abstract: Therapeutic compositions comprising the new derivatives of aminooxodihydroisoindolo-quinazoline of the formula ##STR1## are useful in inhibiting the growth of colon and rectal tumors.Type: GrantFiled: June 20, 1989Date of Patent: December 25, 1990Assignee: Bayer AktiengesellschaftInventors: Valentino Stella, Laman A. Al-Razzak, Hans-Joachim Kabbe